# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and maintains $1 ...
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(...
B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target fr...
HC Wainwright & Co. analyst Mitchell Kapoor downgrades Lyell Immunopharma (NASDAQ:LYEL) from Buy to Neutral and lowers t...
Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed ...
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $6 pric...